Welcome back to BridgeWell Grand Rounds.
I am Dr. Sheri Erwin.
In Episode 1 we established that Sarah has two major upstream drivers.
HPA axis dysregulation with a flat cortisol diurnal curve and depleted adrenal reserve.
And gut-estrobolome dysfunction with elevated zonulin, positive LPS antibodies, and a dysbiosis pattern on her organic acids test.
Today we are going deeper.
Two more upstream questions. What is her metabolic picture doing. And is there a neuroinflammatory component explaining her brain fog and the cognitive symptoms affecting her patient care.
These are the layers that do not show in a standard panel.
And they are almost always present in a patient like Sarah.
When clinicians think about insulin resistance they think about blood sugar and diabetes risk.
But insulin dysregulation has direct consequences for hormonal health that most NP programs never covered.
Here is what insulin resistance does to a hormonal patient.
It drives excess androgen production in the ovaries and adrenal glands.
It disrupts sex hormone binding globulin. Which changes the ratio of free to bound hormones in a way that makes lab values misleading.
It promotes visceral fat accumulation. And visceral fat is metabolically active. It produces its own estrogen through peripheral aromatization. Which disrupts the hormonal balance further.
For a perimenopausal or menopausal patient on BHRT, unaddressed insulin resistance can make the hormonal picture nearly impossible to stabilize.
You adjust the dose. The patient feels better briefly. The insulin resistance reasserts the disruption. The symptoms return.
This is exactly what happened to Sarah in months three and four of her BHRT.
Sarah's fasting glucose is 94. Standard range. No flag on a conventional panel.
But her fasting insulin is 14.2 microinternational units per milliliter.
The conventional reference range goes up to 25. Her result looks normal.
But the functional target is below 8.
At 14.2 she has significant early insulin resistance that fasting glucose would never catch.
Her HOMA-IR calculates to 3.3. Fasting insulin multiplied by fasting glucose divided by 405.
A HOMA-IR above 2.5 indicates clinically significant insulin resistance. Sarah is at 3.3.
Her triglyceride to HDL ratio is 2.8. Above 2.0 in adults is a validated surrogate marker for insulin resistance even when fasting glucose appears normal.
Her HbA1c is 5.4. Conventional normal.
But her fasting insulin tells the real story about what her metabolic state is actually doing.
Sarah has early to moderate insulin resistance. Invisible on a standard metabolic panel. Only visible when you look at fasting insulin and calculate HOMA-IR.
This insulin resistance is directly contributing to her weight gain. Her afternoon energy crashes. And it is disrupting her hormonal environment in exactly the way I described.
The BHRT is working pharmacologically. But the metabolic environment is undermining its effect at the receptor level.
This is why the dose adjustment in month three did not help.
The problem was never the dose.
Sarah's brain fog and word-finding difficulty are the symptoms that concern her most.
She is a clinician. Cognitive clarity is not optional in her work.
And she has not been able to explain it to herself or to anyone else.
Brain fog in a patient like Sarah is almost never a primary neurological problem.
It is a downstream expression of systemic dysfunction.
We have already identified three of the upstream drivers.
HPA axis dysregulation. Gut permeability generating low-grade systemic inflammation. Insulin resistance impairing glucose metabolism at the cellular level including in the brain.
The fourth question is whether there is a neuroinflammatory component amplifying all of those downstream effects.
Sarah's high-sensitivity CRP is 2.8 milligrams per liter.
That systemic inflammatory signal does not stop at the blood-brain barrier.
Neuroinflammation tracks systemic inflammation.
Her homocysteine is 11.4 micromoles per liter. The conventional upper limit is 15. But the functional target is below 8.
Elevated homocysteine is an independent marker of neuroinflammation. And a contributor to cognitive decline when present chronically.
Her ferritin is 94 nanograms per milliliter. Within standard range. But elevated ferritin in the context of elevated CRP functions as an inflammatory marker. Not just an iron storage marker.
Her vitamin D is 31 nanograms per milliliter. Technically in range by conventional standards. The functional target for cognitive and immune protection is 50 to 70.
At 31 she is in insufficiency territory. With well-established downstream effects on inflammation, immune regulation, and mood.
And her magnesium RBC is 4.3 milligrams per deciliter. The functional target is 5.6 to 6.8.
Low magnesium impairs hundreds of enzymatic reactions. Including those involved in energy production, sleep quality, and neurotransmitter synthesis.
We now have four upstream systems assessed.
HPA axis dysregulation. Gut-estrobolome dysfunction. Metabolic insulin resistance. And a neuroinflammatory picture amplified by homocysteine elevation, vitamin D insufficiency, and intracellular magnesium depletion.
None of these showed on the standard workup Sarah had with her previous providers.
They looked at her hormone levels. They looked at her TSH and CBC and basic metabolic panel. They adjusted her BHRT dose. And nothing changed.
Because the problem was never in those markers.
In Episode 3 I am going to bring all four systems together and walk you through exactly how you sequence the interventions.
Which system do you address first. What goes in at each stage. What does the follow-up plan actually look like for a patient like Sarah.
The sequencing is everything. Get it wrong and you are still chasing symptoms.
Thank you for being here.
The clinical companion handouts for this series are available free at bridgewelled.com/case-series. Full lab reference tables with conventional and functional ranges for everything we covered. Go grab those if you have not already.
I will see you in Episode 3.
This is BridgeWell Grand Rounds. I am Dr. Sheri Erwin
